Hidden Statistical Bias May Have Inflated Immunotherapy Hopes in Mesothelioma Trial
A new analysis shows that post-progression censoring may have generated a misleading survival advantage for nivolumab in second-line mesothelioma, resolving ...
A new analysis shows that post-progression censoring may have generated a misleading survival advantage for nivolumab in second-line mesothelioma, resolving ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine